Adverse events such as diarrhea, constipation, nausea, and vomiting associated with the GLP-1 RAs overlap with those seen with cancer treatments, so the patient who is undergoing treatment with an emetogenic regimen for cancer will likely experience additional weight loss, which can lead to nutritional deficiencies, loss of lean muscle mass, and loss of bone mass
Lexarias DehydraTECH eliminated or reduced these as early as their 2024 trials, sharing that Lexarias DehydraTECH-processed Rybelsus capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide compared to commercially available ones
There are oral medications, such as a newly FDA-approved Wegovy pill, which my insurance doesnt cover, either
This multifaceted approach distinguishes Retatrutide from single- or dual-agonist therapies, enabling it to influence multiple physiological pathways that govern appetite, glucose metabolism, and energy expenditure
Over time, this can reduce cravings and help manage weight more effectively
Unfortunately, it's not necessarily all good news